News stories about Ocera Therapeutics (NASDAQ:OCRX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ocera Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.5433464592375 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Ocera Therapeutics (OCRX) traded down 1.4804% during midday trading on Wednesday, reaching $1.0049. The company’s stock had a trading volume of 68,749 shares. The stock has a 50 day moving average price of $1.07 and a 200-day moving average price of $1.10. Ocera Therapeutics has a 52-week low of $0.52 and a 52-week high of $2.95. The company’s market capitalization is $26.64 million.
Ocera Therapeutics (NASDAQ:OCRX) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.01. Equities research analysts expect that Ocera Therapeutics will post ($1.40) EPS for the current year.
Separately, Zacks Investment Research upgraded Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective on the stock in a research note on Saturday, August 26th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Ocera Therapeutics currently has an average rating of “Hold” and a consensus target price of $2.25.
COPYRIGHT VIOLATION NOTICE: This story was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.com-unik.info/2017/11/01/ocera-therapeutics-ocrx-earns-media-sentiment-score-of-0-08.html.
About Ocera Therapeutics
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
What are top analysts saying about Ocera Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ocera Therapeutics Inc. and related companies.